AKT1 and colorectal carcinoma: IL-6 can inhibit the chemotherapeutic efficacy of 5-FU, the most commonly used chemotherapy for CRC, by activating the IL-6R/GP130 signaling pathway and the levels of P-AKT, P-ERK and P-STAT3 [24].